EDAP Technomed's Ablatherm
This article was originally published in The Gray Sheet
Executive Summary
Clinical trial of the high intensity focused ultrasound (HIFU) system for prostate cancer treatment commences at Georgetown University Medical Center under an investigational device exemption approved Jan. 8. Baylor University and the University of California at San Francisco also will participate in the 120-patient trial, which will enroll those who already have been treated with radiation but have experienced a recurrence
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.